Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.5083 EUR
−140.38 M EUR
39.82 M EUR
58.57 M
About Merus N.V.
Sector
Industry
CEO
Sven Ante Lundberg
Website
Headquarters
Utrecht
Founded
2003
ISIN
NL0011606264
FIGI
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of A2AKFX is 40.2000 EUR — it has increased by 1.01% in the past 24 hours. Watch Merus N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Merus N.V. stocks are traded under the ticker A2AKFX.
A2AKFX stock has risen by 3.08% compared to the previous week, the month change is a −4.29% fall, over the last year Merus N.V. has showed a −15.90% decrease.
We've gathered analysts' opinions on Merus N.V. future price: according to them, A2AKFX price has a max estimate of 104.98 EUR and a min estimate of 64.53 EUR. Watch A2AKFX chart and read a more detailed Merus N.V. stock forecast: see what analysts think of Merus N.V. and suggest that you do with its stocks.
A2AKFX stock is 1.52% volatile and has beta coefficient of 1.08. Track Merus N.V. stock price on the chart and check out the list of the most volatile stocks — is Merus N.V. there?
Today Merus N.V. has the market capitalization of 2.70 B, it has increased by 4.31% over the last week.
Yes, you can track Merus N.V. financials in yearly and quarterly reports right on TradingView.
Merus N.V. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
A2AKFX earnings for the last quarter are −1.31 EUR per share, whereas the estimation was −0.77 EUR resulting in a −69.72% surprise. The estimated earnings for the next quarter are −0.89 EUR per share. See more details about Merus N.V. earnings.
Merus N.V. revenue for the last quarter amounts to 10.57 M EUR, despite the estimated figure of 7.79 M EUR. In the next quarter, revenue is expected to reach 10.49 M EUR.
A2AKFX net income for the last quarter is −89.73 M EUR, while the quarter before that showed −46.72 M EUR of net income which accounts for −92.06% change. Track more Merus N.V. financial stats to get the full picture.
No, A2AKFX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 11, 2025, the company has 229.00 employees. See our rating of the largest employees — is Merus N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Merus N.V. EBITDA is −205.19 M EUR, and current EBITDA margin is −350.44%. See more stats in Merus N.V. financial statements.
Like other stocks, A2AKFX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merus N.V. stock right from TradingView charts — choose your broker and connect to your account.